CN111630045A - 喹啉衍生物的结晶 - Google Patents

喹啉衍生物的结晶 Download PDF

Info

Publication number
CN111630045A
CN111630045A CN201980011060.4A CN201980011060A CN111630045A CN 111630045 A CN111630045 A CN 111630045A CN 201980011060 A CN201980011060 A CN 201980011060A CN 111630045 A CN111630045 A CN 111630045A
Authority
CN
China
Prior art keywords
compound
crystals
crystal
formula
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980011060.4A
Other languages
English (en)
Inventor
赵锐
李新路
刘飞
张喜全
杨铁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202210428672.7A priority Critical patent/CN114716410A/zh
Publication of CN111630045A publication Critical patent/CN111630045A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请涉及医药领域，涉及喹啉衍生物的结晶，具体涉及喹啉衍生物水合物、甲醇化物、四氢呋喃化物的结晶和无定型物，以及所述结晶的制备方法、含所述结晶的药物组合物和在医药领域的用途。本申请还提供其制备方法，收率高，结晶条件温和，适合工业化生产，能够更好地满足制药业需求。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201980011060.4A 2018-02-11 2019-01-31 喹啉衍生物的结晶 Pending CN111630045A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210428672.7A CN114716410A (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101405060 2018-02-11
CN201810140506 2018-02-11
PCT/CN2019/074183 WO2019154273A1 (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210428672.7A Division CN114716410A (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶

Publications (1)

Publication Number Publication Date
CN111630045A true CN111630045A (zh) 2020-09-04

Family

ID=67548139

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210428672.7A Pending CN114716410A (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶
CN201980011060.4A Pending CN111630045A (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210428672.7A Pending CN114716410A (zh) 2018-02-11 2019-01-31 喹啉衍生物的结晶

Country Status (2)

Country Link
CN (2) CN114716410A (zh)
WO (1) WO2019154273A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109748904A (zh) * 2019-01-31 2019-05-14 正大天晴药业集团股份有限公司 喹啉衍生物的结晶

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325958A (zh) * 2005-12-09 2008-12-17 艾博特公司 结晶态来他替尼(lestaurtinib)水合物和结晶态来他替尼半水合半乙腈化物和结晶态来他替尼半水合半四氢呋喃化物
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
WO2016179123A1 (en) * 2015-05-04 2016-11-10 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438B (zh) * 2010-08-01 2014-02-19 正大天晴药业集团股份有限公司 喹啉衍生物的结晶及其制备方法
CN108864050B (zh) * 2018-07-25 2019-12-10 上海博璞诺科技发展有限公司 一种合成安罗替尼及其盐酸盐的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325958A (zh) * 2005-12-09 2008-12-17 艾博特公司 结晶态来他替尼(lestaurtinib)水合物和结晶态来他替尼半水合半乙腈化物和结晶态来他替尼半水合半四氢呋喃化物
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
WO2016179123A1 (en) * 2015-05-04 2016-11-10 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕扬 杜冠华: "《晶型药物》", 31 October 2009, 人民卫生出版社 *

Also Published As

Publication number Publication date
CN114716410A (zh) 2022-07-08
WO2019154273A1 (zh) 2019-08-15

Similar Documents

Publication Publication Date Title
JP4836404B2 (ja) 抗癌化合物ｚｄ１８３９の新規結晶形
CN107531682B (zh) B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
EA038195B1 (ru) Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
CN112047892B (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
CN107531678B (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
JP7379680B2 (ja) テルフェニル化合物の新規な塩
WO2011009095A1 (en) Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
CN112047893B (zh) 吉非替尼与水杨酸共晶体
WO2018045043A1 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US10513513B2 (en) Salts of quinazoline derivative or crystals thereof, and the process for producing thereof
US11352368B2 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
US9453011B2 (en) Crystal form of dabrafenib mesylate and preparation method thereof
WO2020061996A1 (zh) 氘代azd9291化合物的新晶型及其用途
US20220098172A1 (en) Crystals of quinolone derivatives
CN111630045A (zh) 喹啉衍生物的结晶
WO2022063229A1 (zh) 含芳氨基喹唑啉的化合物的盐及其制备方法和应用
CN111601791B (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
US9688687B2 (en) Polymorphic forms of icotinib phosphate and uses thereof
JP2018002644A (ja) （Ｓ）−Ｎ−（４−アミノ−５−（キノリン−３−イル）−６，７，８，９−テトラヒドロピリミド［５，４−ｂ］インドリジン−８−イル）アクリルアミドの結晶
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
AU2022395869A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
TW202313614A (zh) 咪唑啉酮衍生物的晶型
CA3240466A1 (en) Salt of 3,4-dihydroisoquinoline compound and use thereof
CN117769560A (zh) Egfr抑制剂的盐、晶型及其组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200904

RJ01 Rejection of invention patent application after publication